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Real-practice thromboprophylaxis in atrial fibrillation
This retrospective observational study was based on data-
bases of the Local Health Authority of Treviso, Italy. It 
evaluated the prevalence and the effectiveness of oral anti-
coagulation treatment (OAT) for the management of non-
valvular atrial fibrillation (NVAF) in everyday clinical 
practice. Out of 6,138 NVAF patients, only 3,024 received 
vitamin K antagonist (VKA). Potential barriers decreasing 
the probability of being treated with VKA were female sex, 
older age, antiplatelet treatment and history of bleeding. In 
addition, VKA-treatment was not in line with current ESC 
and AIAC guidelines, since the patients at high or low risk 
of stroke were under- or over-treated, resp. Among VKA-
treated patients, 73 % of subjects were not at target with 
anticoagulation. OAT resulted to be effective in reducing 
stroke risk. However, stroke events were significantly influ-
enced also by previous stroke or transient ischemic attack 
(hazard ratio, HR = 2.99, p < 0.001) and by previous bleeding 
events (HR = 1.60, p < 0.001).
Keywords: atrial fibrillation, thromboprophylaxis, real-
practice, vitamin K antagonists, stroke risk
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major 
preventable cause of stroke and hospitalization (1, 2). Its prevalence has increased over 
years (3); in Italy it was found to be 1.9 % (4, 5).
This arrhythmia confers, on average, a five-fold risk of stroke, doubles the risk of 
mortality, increases the risk of heart failure and is responsible for one-fifth of all strokes. 
In addition, strokes caused by AF tend to be more frequently fatal, disabling and recurring 
when compared to other causes of stroke (6–9).
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Current ESC and AIAC guidelines (10, 11) recommend oral anticoagulation therapy 
(OAT) for AF patients at high risk of stroke, according to CHADS2 or CHA2DS2-VASC 
scores of individual risk. In particular, anticoagulant treatment is highly recommended for 
patients with CHADS2 or CHA2DS2-VASC scores ≥ 2. However, even if oral anticoagula-
tion is effective in preventing strokes due to AF (12), there is extensive evidence suggesting 
that this therapy remains underused (4, 10, 13–15). Despite, the data from the literature is 
clearly showing that the efficacy of antiplatelet agents in thromboembolic prevention is 
significantly lower than that of oral anticoagulant therapy (14). Antiplatelet agents are of-
ten used in substitution of the oral anticoagulant agents. Also, among patients treated with 
vitamin K antagonist (VKA) the quality of anticoagulation control is often poor (14) and 
many discontinue treatment permanently (16). In Italy, strokes connected to the absence of 
treatment or related to an inadequate control of INR are estimated to be around 11,000 per 
year (17). Given the recognized limitations of VKA, the availability of novel oral antico-
agulants could represent a valid alternative therapy to minimize stroke risk and to guar-
antee an appropriate management of AF.
The aims of this study were to evaluate if the anticoagulant treatment of non-valvular 
AF (NVAF) in real clinical practice is in line with current guideline recommendations, and 
to assess the role of the oral anticoagulant treatment in the prevention of stroke in every-
day clinical practice.
EXPERIMENTAL
A retrospective observational cohort study was conducted in the Local Health Au-
thority (LHA) of Treviso, Italy, from January 1, 2007 to December 31, 2013 using several 
databases containing an annual mean of 409,000 subjects. All information was collected 
from national databases of the Health Care Authority, which contain information related 
to age, sex, prescriptions and pathologies. Additionally, local databases with information 
on international normalized ratio (INR) monitoring and hospital admissions were used 
and linked with previously detected data. This article does not contain any studies with 
human participants or animals performed by any of the authors.
The eligible population included all participants hospitalized with a diagnosis of 
atrial fibrillation (ICD-9 CM 427.3) during a hospital admission (considered as the index 
date, ID), resident in the LHA of Treviso. Exclusion criteria were: valvular AF defined ac-
cording to the current guidelines (18), patients who died within 7 days from the diagnosis 
and patients who received the anticoagulant therapy occasionally (= number of prescrip-
tions which covered less than 6 months in continuation) (Fig. 1). The follow-up period was 
defined as the time between the ID and 31 December 2013 or death date. 
Two different populations with non valvular atrial fibrillation were defined to answer 
the study objectives: N-VKA group – participants who did not receive any VKA treatment 
and VKA group – participants who received at least 6 months of VKA treatment.
The individual stroke risk for each patient was defined according to CHADS2 and 
CHA2DS2-VASC scores (19–21). The CHADS2 score was the sum of points obtained after 
addition of one point each for heart failure, hypertension, age ≥ 75 and diabetes, and two 
points for previous stroke/transient ischemic attack (TIA). The CHA2DS2-VASC score was 
the sum of points after addition of one point each for heart failure, hypertension, diabetes, 
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vascular disease, age 60–74 and female sex, and two points each for previous stroke or 
transient ischemic attack, previous systemic embolism and age ≥ 75. Given the 7-years fol-
low up study, both scores have been considered.
Use of antiplatelet agents, non-steroidal anti-inflammatory drugs and corticosteroids 
before the ID were considered. Similarly, hospitalizations with a diagnosis of bleeding 
occurring before the ID were considered, as well.
Subgroups defined according to therapeutic categories and risk of stroke
All drugs were identified through the international anatomical therapeutic chemical 
classification system (ATC code).
Vitamin K antagonist users were identified through the prescription of warfarin or 
acenocumarol (ATC B01AA). In addition, INR controls were collected and reported as the 
time in therapeutic range (TTR) (22). To calculate TTR, each patient should have a sufficient 
number of INR controls, i.e., one INR control per month according to the guidelines (18).
Antiplatelet agent prescriptions where identified through the ATC B01AC. To determine 
the influence of risk factors and treatments on occurrence of stroke, a multivariate regression 
analysis (Cox analysis) was performed, with regard to age, sex, previous heart failure, 
hypertension, diabetes mellitus, stroke/TIA, myocardial infarction, previous bleeding, pre-
vious or concomitant use of antiplatelet agents, non-steroidal anti-inflammatory drugs and 
corticosteroids. The contribution of CHADS2-VASC or CHADS2 scores was evaluated as 
well. However, since they also include information on age, sex and previous stroke or TIA, 
they were not included in this analysis. According to the treatment, four subcategories were 
therefore identified (Fig. 2) and also included in the regression analysis: group VKA, TTR 
≥ 65 % – participants who received VKA treatment for at least 6 months and reached the 
target (14); group VKA, TTR < 65 % – participants who received at least 6 months of VKA 
treatment and did not reach the target (14); N-VKA, N-antiplatelet group – participants who 
did not receive either VKA or antiplatelet treatment; N-VKA, antiplatelet+ group – partici-
pants who received only antiplatelet drugs for at least of 6 months.
The first stroke recorded after the ID, defined as the first hospital admission with di-
agnosis of stroke, was considered. 
Fig. 1. Flow chart of patients with non-valvular atrial fibrillation. AF – atrial fibrillation, VKA – vita-
min K antagonist.
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Data analysis
The baseline characteristics of the populations were reported by means or medians 
and standard deviations (SDs) for quantitative information and with frequencies and per-
centages for qualitative characteristics. Statistical differences were identified with a t-test 
or chi-square analysis.
To define possible associations between risk factors and occurrence of stroke, a pre-
liminary univariate analysis was made. Statistical analysis was performed using STATA 
software version 14. Two-sided statistical significance was considered with significance 
level < 0.05, < 0.01 and < 0.001.
RESULTS AND DISCUSSION
This 7-year follow up study was aimed to describe the anticoagulation therapy in 
patients with atrial fibrillation. Applying the inclusion and exclusion criteria, 6138 partici-
pants were considered as eligible for the study (Fig. 1). The baseline characteristics of the 
NVAF population are reported in Table I.
Among patients with NVAF, about 60 % received a first prescription of VKA after the 
ID. The underuse of oral anticoagulant treatment is well-documented in the literature: a 
recent meta-analysis of quantitative studies revealed that less than 70 % of high-risk pa-
tients receive adequate oral anticoagulation therapy (13).
In our study, statistical differences were found between VKA-treated and non-treated 
patients for the most part of the considered baseline characteristics, except for the follow-
ing: prior stroke/TIA, peripheral artery disease and NSAID/corticosteroids use (Table I). 
These differences reflected the clinical judgement on deciding whether patient should be 
treated or not, i.e., if the risk/benefit profile of the treatment was positive. In particular, 
female sex, increasing age (≥ 75), antiplatelet drugs and history of major bleeding, resulted 
negatively to the possibility of receiving VKA therapy. Also, different studies have identi-
fied inadequate risk stratification; the advanced age of the patient, bleeding and falling 
risk, and the difficulties of warfarin management, including adverse events and patient 
compliance, as potential barriers to an appropriate treatment prescription (13, 15, 23).
Fig. 2. Flow chart of subcategories identified by treatment. N-antiplatelet – patients not treated with 
antiplatelet agent, N-VKA – patients not treated with vitamin K antagonist, TTR – time in therapeutic 
range, VKA – vitamin K antagonist.
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Table I. Baseline characteristics, VKA group vs. N-VKA group
Total population
(n = 6,138)
VKA group
(n = 3,024)
N-VKA group
(n = 3,114)
p-
value
Age (y) 75.59 ± 11.51 75.09 ± 8.90a 76.08 ± 13.67b < 0.001
Sex
Male (%) 3053 (49.7) 1594 (52.7) 1459 (46.9) < 0.001
Female (%) 3085 (50.3) 1430 (47.3) 1655 (53.1) < 0.001
Follow up (death or study 
end date, i.e., 31.12.2013) 
(median month ± min-max)
37.70 (0–85.17) 48.73 (6.70–85.17) 23.47 (0–85.13)
Thromboembolic risk factors
Prior heart failure 1726 (28.12)   951 (31.45)   775 (24.89) < 0.001
Prior hypertension 4045 (65.90) 2177 (72.00) 1868 (60.00) < 0.001
Age ≥ 75 y 3651 (59.48) 1810 (59.85) 2058 (66.09) < 0.001
Prior diabetes 1272 (20.72)   676 (22.35)   596 (19.14) < 0.001
Prior stroke/TIA 1089 (17.74)   519 (17.16)   570 (18.30) ns
Prior peripheral artery 
disease (including myocar-
dial infarction)
  868 (14.14)   413 (13.66)   455 (14.61) ns
CHA2DS2-VASC
0   297 (4.84)     67 (2.31)   230 (7.39) < 0.001
1   504 (8.21)   197 (6.51)   307 (9.86) < 0.001
≥ 2 5337 (86.95) 2760 (91.27) 2577 (82.75) < 0.001
CHADS2
0   815 (13.28)   252 (8.34)   563 (18.08) < 0.001
1 1435 (23.38)   762 (25.20)   673 (21.61) < 0.001
≥ 2 3888(63.34) 2010 (66.47) 1878 (60.31) < 0.001
Antiplatelet agents 
at baseline 2504 (40.79) 1146 (37.90) 1358 (43.61) < 0.001
Antiplatelet agents after AF 
diagnosis 1742 (28.38)   340 (11.24) 1402 (45.02) < 0.001
NSAID 2111 (34.39) 1064 (35.18) 1047 (33.62) ns
History of major bleeding   279 (4.55)     80 (2.62)   199 (6.39) < 0.001
95 % confidence interval: a 74.77–75.40, b 75.61–76.56.
ns – not significant difference, NSAID – nonsteroidal anti-inflammatory drugs, N-VKA group – patients not treat-
ed with vitamin K antagonist, TIA – transient ischemic attack, VKA group – patients on vitamin K antagonist 
therapy
Values are mean ± SD, median or %.
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Of total of VKA-treated patients, 1,820, ca 37 % patients discontinued the anticoagulant 
treatment within 6 months. This rate of discontinuation is similar to what has been reported 
in the literature, where discontinuation rate ranges from 20 to more than 50 % (15, 24).
Although European clinical guidelines would have influenced practice strongly recom-
mending thromboprophylaxis in high risk patients and no treatment in low risk patients 
(CHA2DS2-VASC or CHADS2 score) (10, 18), we still found a suboptimal use of antithrom-
botic therapy.  According to CHA2DS2-VASC and CHADS2 respectively, 82.8 and 60.3 % 
in the N-VKA group, resp., did not receive the therapy despite the score ≥2 indicating a 
major stroke risk. Our findings highlight therefore underuse of anticoagulants among 
high thromboembolic risk patients. This remains a persistent problem together with an 
elevated rate of discontinuation.
On the other hand, 2.3 % of patients in the VKA group received a thromboprophy-
laxis although their score was zero. Zimetbaum et al. (25) found similar proportions of 
patients in the low, moderate and high stroke-risk groups receiving warfarin. Thus, pa-
tients who would benefit the most from anticoagulants due to high risk of stroke do not 
receive treatment, while those considered at low risk may perhaps be unnecessarily ex-
posed to the inconvenience and risks associated with anticoagulant therapy (23, 26).
Comparing the antiplatelet treatment before and after the ID, we observed a discon-
tinuation rate of around 70 % in the VKA-group. Otherwise, the antiplatelet treatment in 
N-VKA group increased up to 45.0 %. Despite the data from the literature clearly showing 
that the efficacy of antiplatelet agents in thromboembolic prevention is significantly lower 
than that of oral anticoagulant therapy (14), the present study revealed that general prac-
titioners preferred to use antiplatelet agents in about 45 % of N-VKA-treated patients. This 
behavior could be partially explained by specific contraindications to VKA, difficulties in 
performing the INR control, concerns over bleeding risk and the elevated age of treated 
patients. However, further analysis should be performed in order to investigate the reason 
of a large use of antiplatelet therapy instead of a VKA treatment in order to identify which 
patients will benefit the most by switching from an antiplatelet drug to an oral anticoagu-
lant treatment. Clearly, concerns over bleeding risk lead physicians to not prescribing a 
VKA treatment, since history of major bleeding events was more frequent among the 
group of no treated patients (6.4 and 2.6 % of N-VKA and VKA patients, resp.).
Of note, the median follow-up period was very different between groups: 48.73 and 
23.47 months for the VKA and N-VKA groups, resp. (p < 0.001). No specific reason was 
detected to justify this difference.
The TTR was calculated for the 3,024 patients in the VKA group: overall, the mean 
TTR was 55.76 (± 14.83) months and only 27.2 % of patients reached the target (TTR ≥ 65 %), 
with an increase over years from 24.6 % in 2007 to 37.2 % in 2013. Such a result is particu-
larly dramatic, since a recent study by Connolly et al. (14) highlighted that TTR < 65 % 
abolishes the protective effect of oral anticoagulant therapy and reaches that comparable 
to antiplatelet agents.  Comparable results were found only in the study of Sarawate et al. 
(27) where the average TTR was 28.6 months. Differently from the present study, most 
prior observational studies reporting higher TTR were conducted in patients in hospital 
setting, under supervision of hospital-based physicians or by anticoagulation clinics (28). 
What is evident in this real world study performed in a community setting covering a long 
period of time, is a persisting difficulty for general practitioners of managing especially 
elderly patients (aged 75 or older) affected by several comorbidities. 
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Stroke risk
In Table II, the clinical outcome, i.e., stroke events, was subject to a multivariate regres-
sion analysis.
Increasing age was a major risk factor for stroke (HR =1.82, 2.97 and 4.48 for patients 
aged 65–74, 75–84 and ≥ 85, respectively, p < 0.001). With regard to comorbidities, previous 
stroke/TIA (HR = 2.99, p < 0.001) and previous bleeding events (HR = 1.60, p < 0.001) were 
Table II. Hazard ratio (HR) for stroke risk evaluation (Cox regression model)
Anamnestic information
Multivariate analysis
No. patients Hazard ratio SE p-valuea 95 % CI
Sex
Male 3,053
Female 3,085 0.913 0.076 0.273 0.814–1.119
Age class (y)
< 65 922
65–74 1,565 1.824 0.362 0.002 1.237–2.690
75–84 2,304 2.971 0.558 < 0.001 2.056–4.294
≥ 85 1,347 4.475 0.886 < 0.001 3.036–6.595
Previous stroke/TIA
No 5,049
Yes 1,089 2.986 0.249 < 0.001 2.535–3.517
Previous bleeding events
No 5,859
Yes 279 1.598 0.203 < 0.001 1.246–2.049
Antiplatelet agents 
at baseline
No 3,634
Yes 2,504 1.460 0.123 < 0.001 1.238–1.721
Therapeutic management
N-VKA, N-antiplatelet 1,712
N-VKA, antiplatelet+ 1,402 0.916 0.114 0.483 0.717–1.170
VKA, TTR < 65% 2,201 0.786 0.089 0.034 0.629–0.982
VKA, TTR ≥ 65% 823 0.594 0.094 0.001 0.435–0.810
a p-value beyond |z|.
CI – confidence interval, N-antiplatelet – patients not treated with antiplatelet agent, NSAID – nonsteroidal anti-in-
flammatory drug, N-VKA group – patients not treated with vitamin K antagonist, SE – standard error, TIA – transient 
ischemic attack, TTR – time in therapeutic range, VKA – group of patients on vitamin K antagonist therapy
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significantly associated with the risk of stroke, thus confirming the well-documented role 
of these factors in risk determination (20).
Similarly, the use of antiplatelet agents at baseline significantly increased stroke risk 
(HR = 1.46, p < 0.001), probably because patients treated with these drugs were more com-
plex in term of cardiovascular complications. On the other hand, sex was no significantly 
associated with stroke risk (HR = 0.91).
According to the treatments, the N-VKA, N-antiplatelet group was considered the 
group with the highest stroke risk. The addition of antiplatelet drug (N-VKA, antiplatelet 
+ group) did not allow a significant decrease in such a risk (HR = 0.92). VKA treatment 
significantly reduced the stroke risk, as extensively described in the literature (14). In fact, 
the VKA group with TTR < 65 % had an HR = 0.79 (p < 0.05). Such a risk further decreased 
to 0.59 (p < 0.01) for patients with TTR ≥ 65 % (VKA group, TTR ≥ 65 %).
CONCLUSIONS
In conclusion, better quality of care of AF patients should be provided by increasing 
adherence to anticoagulation guidelines and improving patients compliance with antico-
agulation therapy through education and established protocols. A systematic approach 
should be implemented in order to assess the presence of stroke risk factors, to determine 
the presence of specific contraindications, and to schedule and ensure an appropriate fol-
low-up and INR control. The introduction of novel oral anticoagulant may facilitate better 
adherence due to ease of administration and reduced monitoring burden. Further analysis 
comparing VKA vs. non oral anticoagulant therapy should be performed.
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